French molecular nuclear medicine specialist Advanced Accelerator Applications (Nasdaq: AAAP) has had the results of a Phase III study of its drug Lutathera (lutetium-177 dotatate) published in the New England Journal of Medicine.
The Netter-1 study is evaluating Lutathera in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors (NETs).
Newly-published results have added to AAA’s confidence that this drug can enhance the current standard of care in the condition, and its share price was up by 3.5% at $28.84 in pre-market on Thursday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze